Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising results in preliminary clinical trials . https://socialdosa.com/story11369446/retatrutide-emerging-studies-and-potential-medical-roles